TickerTalks
Browse all tickers →
TickerTalks›$AZN
AZAZN

AstraZeneca PLC

$AZN·$131B·Drug Manufacturers - General·Healthcare
$169.34+2.9%YTD-8.5%1Y+21.2%
Mentions · last 7 days
2026-07-14: 67 posts2026-07-15: 33 posts2026-07-16: 14 posts2026-07-17: 11 posts2026-07-18: 6 posts2026-07-19: 5 posts2026-07-20: 14 posts160-39%
Price updated 1h ago·X counts updated 1d ago
AZAZN
$AZNAstraZeneca PLC
$169.34+2.93%160 posts-39%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AZN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-20

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

The UK pharma heads into earnings with Nature-published CAR-T data and a fresh securities investigation.

AstraZeneca is one of the world's largest pharma companies with a diversified oncology, respiratory, rare disease, and cardiovascular franchise — plus a growing CAR-T and ADC pipeline through partnerships. Down 9% YTD as a mixed pipeline year weighs, heading into July 27 earnings on real oncology progress.

The setup:

  • Fundamentals are firmly positive: Q1 revenue $15.3B (+12.5% YoY) at 80% gross margin and 24% operating margin — this is exactly what a diversified big pharma should look like, and consensus Q2 EPS $2.50 is a beat-friendly bar given the trajectory.
  • The Nature CAR-T publication is category-defining: reported AstraZeneca and AbelZeta published the first full human data for the armored GPC3-CAR-T C-CAR031 (AZD7003) in Nature — publishing first human data in Nature is the gold-standard scientific validation, and positions AZN as a serious CAR-T player alongside partnership plays.
  • The Levi & Korsinsky investigation is background noise: reported securities investigation announcement — these follow essentially every pharma company after specific pipeline setbacks (eplontersen data was cited as negative read-through in the NTLA verdict), but rarely resolve against management on real merits.

Event-ahead into July 27 with real oncology-pipeline progress — a Q2 EPS beat plus commentary on the CAR-T C-CAR031 program timeline and any additional oncology-partnership updates extends the run higher; a soft print or a fresh pipeline setback extends the pullback to $155 support. The dividend and defensive positioning provide real cushion.

Agrees with X sentimentThe X read on the Nature CAR-T publication and the ABVX prior takeover chatter (took break for $920M capital raise) is directionally right on the oncology-strategic-expansion thesis. The ATTR-CM failure simplifies TAM for BBIO Attruby framing is a fair adjacent-market read.

What to watch: July 27 Q2 earnings: EPS vs $2.50, revenue growth trajectory, updated FY guide, CAR-T C-CAR031 program timeline, and any additional oncology-partnership updates. A fresh pipeline setback extends the pullback to $155 support.

On the calendar: 2026-07-27 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment7 posts analyzed · as of 2026-07-20

AstraZeneca appears across several unrelated pharma threads without a single dominant catalyst. Posts note AZN and Lilly reportedly resuming takeover interest in Abivax after Abivax's roughly $920M raise strengthened its negotiating hand, and separately highlight first full human data for the AbelZeta-partnered GPC3 CAR-T C-CAR031 in advanced HCC, showing a 44.4% ORR. A BBIO-focused post frames a Salim-related AZN failure as clearing the ATTR-CM landscape for competitors, and other notes reference AZN as a comparator in oncology and breast-cancer analyst calls. Sentiment is mixed and clinical-development driven.

Read the AI verdict + X sentiment for $AZN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AZN.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $AZN

Neutral — Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios; limited read-through from drug manufacturers - general macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+18.7%YTD
+50.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
27.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
12.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$2.58$2.57+0.4%
Q4 2025Feb 10, 2026$2.12$2.18-2.8%
Q3 2025Nov 6, 2025$2.38$2.29+3.9%
Q2 2025Jul 29, 2025$2.18$2.16+0.9%
Next earningsMon, Jul 27·consensus EPS $2.50

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.3B+12.5%82.5%27.8%$1.99$1.8B
Q4 FY25$15.5B+4.1%79.9%19.2%$1.51$1.4B
Q3 FY25$15.2B+12.0%81.6%23.6%$1.63$4.4B
Q2 FY25$14.5B+11.7%82.9%24.3%$1.58$1.5B

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$63.2B$62.5B – $64.5B$10.24$10.09 – $10.4817
FY27$67.5B$66.5B – $68.5B$11.56$11.22 – $11.7817
FY28$71.8B$71.5B – $72.2B$12.90$9.57 – $13.8520
FY29$77.1B$73.4B – $79.1B$14.95$14.03 – $15.4811
FY30$81.8B$77.9B – $84.0B$16.43$15.42 – $17.0011

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.36%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-10.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 770.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.235-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 20Mani SharmaSee Remarks11.9K sh$2.2M
+ 4 other (4 awards) in window

See when $AZN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMar 193
SC 13D/AActivist amendmentFeb 6SC 13D/A
+ 69 other (54 6-Ks · 3 CERTs · 3 8-A12Bs · 2 25-NSEs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com·1d agoAstrazeneca Plc $AZN Shares Sold by Boston Common Asset Management LLCdefenseworld.net·2d agoAstrazeneca Plc $AZN Shares Acquired by DekaBank Deutsche Girozentraledefenseworld.net·2d agoAI Bubble Risks Make Dividend Stocks Attractive Againseekingalpha.com·3d agoThe First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?247wallst.com·5d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$MRK$ABBV$OGN$BMY
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport